Title: Impact of fluorodihydroxyphenylalanine-(18F) PET on management of adult patients with documented or occult digestive endocrine tumors Short title: FDOPA PET and digestive endocrine tumors

Abstract Context and Objectives : Fluorodihydroxyphenylalanine–(18F) (FDOPA) positron emission tomography (PET) is a recent imaging modality used to localize endocrine tumors. This study was conducted to evaluate the impact of FDOPA-PET on the management of patients referred for carcinoid or noncarcinoid digestive tumors and the clinical relevance of the treatment decisions based on this examination. Methods and Patients: Between March 2002 and December 2006, 101 FDOPA-PET examinations were performed in 78 adult patients for follow-up of histologically documented carcinoid tumor of the ileum (23 patients) or noncarcinoid digestive tumor (26 patients), or to screen for occult digestive endocrine tumors (29 patients). More than one FDOPA-PET examination was performed in 12 patients. The impact of FDOPA PET was evaluated on a per patient basis by means of a questionnaire completed by the referring physician and the relevance of the treatment decision was assessed on the basis of follow-up data.

[1]  R. Parkkola,et al.  Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. , 2007, The Journal of clinical endocrinology and metabolism.

[2]  E. Nitzsche,et al.  Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. , 2001, Radiology.

[3]  E. D. de Vries,et al.  Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Couvelard.  Tumeurs endocrines gastro-intestinales : particularités morphologiques et clinico-pathologiques , 2005 .

[5]  C. Capella,et al.  Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[6]  H. Huopio,et al.  Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. , 2006, Diabetes.

[7]  Janet R. Saffer,et al.  Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. , 2007, The Journal of clinical endocrinology and metabolism.

[8]  P. Valk,et al.  The impact of PET on the management of lung cancer: the referring physician's perspective. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  J. Talbot,et al.  Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Georgios Karanikas,et al.  Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. Bergström,et al.  Pancreatic neuroendocrine tumors: diagnosis with PET. , 1995, Radiology.

[12]  N. Boddaert,et al.  Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  P. Valk,et al.  Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  K Wienhard,et al.  F-Dopa as an amino acid tracer to detect brain tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  E. Nitzsche,et al.  Imaging of a Metastatic Gastrointestinal Carcinoid by F-18-DOPA Positron Emission Tomography , 1999, Nuklearmedizin.

[16]  Michael E. Phelps,et al.  Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma , 2001 .